Biostent cytochalasin B: Will start in March a Phase I safety trial of four different doses and placebo, in 40 angioplasty patients

NeoRx Corp. (NERX), Seattle
Product:

Read the full 51 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE